Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
British Journal of Cancer
|
August 23, 2000
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators
C Gridelli, L Frontini, F Perrone, et al.
British Journal of Cancer
|
March 1, 2002
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen
S Cascinu, A M Baldelli, V Catalano, et al.
Oncology
|
October 2, 2004
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up
S Barni, E Piazza, L Frontini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2002
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
G V Scagliotti, F De Marinis, M Rinaldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1997
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer
R Labianca, S Cascinu, L Frontini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers
A Sobrero, A Zaniboni, G L Frassineti, et al.
British Journal of Cancer
|
May 27, 2004
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
M Di Maio, C Gridelli, C Gallo, et al.
British Journal of Cancer
|
October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A Ruzzo, F Graziano, Fabio Galli, et al.
Journal of Cancer Policy
|
October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
ESMO Open
|
December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
British Journal of Cancer
|
August 23, 2000
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators
C Gridelli, L Frontini, F Perrone, et al.
British Journal of Cancer
|
March 1, 2002
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen
S Cascinu, A M Baldelli, V Catalano, et al.
Oncology
|
October 2, 2004
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up
S Barni, E Piazza, L Frontini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2002
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
G V Scagliotti, F De Marinis, M Rinaldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1997
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer
R Labianca, S Cascinu, L Frontini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers
A Sobrero, A Zaniboni, G L Frassineti, et al.
British Journal of Cancer
|
May 27, 2004
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
M Di Maio, C Gridelli, C Gallo, et al.
British Journal of Cancer
|
October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A Ruzzo, F Graziano, Fabio Galli, et al.
Journal of Cancer Policy
|
October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
ESMO Open
|
December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Page
of 7